122 related articles for article (PubMed ID: 29693080)
1. Nevus anemicus and RASopathies.
Bulteel C; Morren MA; De Haes P; Denayer E; Legius E; Brems H
JAAD Case Rep; 2018 May; 4(4):390-391. PubMed ID: 29693080
[No Abstract] [Full Text] [Related]
2. Interaction between a Domain of the Negative Regulator of the Ras-ERK Pathway, SPRED1 Protein, and the GTPase-activating Protein-related Domain of Neurofibromin Is Implicated in Legius Syndrome and Neurofibromatosis Type 1.
Hirata Y; Brems H; Suzuki M; Kanamori M; Okada M; Morita R; Llano-Rivas I; Ose T; Messiaen L; Legius E; Yoshimura A
J Biol Chem; 2016 Feb; 291(7):3124-34. PubMed ID: 26635368
[TBL] [Abstract][Full Text] [Related]
3. Legius syndrome, an Update. Molecular pathology of mutations in SPRED1.
Brems H; Legius E
Keio J Med; 2013; 62(4):107-12. PubMed ID: 24334617
[TBL] [Abstract][Full Text] [Related]
4. Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.
Witkowski L; Dillon MW; Murphy E; S Lebo M; Mason-Suares H
Mol Genet Genomic Med; 2020 Apr; 8(4):e1180. PubMed ID: 32107864
[TBL] [Abstract][Full Text] [Related]
5. Nevus anemicus in neurofibromatosis type 1: a potential new diagnostic criterion.
Marque M; Roubertie A; Jaussent A; Carneiro M; Meunier L; Guillot B; Pinson L; Pinson S; Bessis D
J Am Acad Dermatol; 2013 Nov; 69(5):768-775. PubMed ID: 23972508
[TBL] [Abstract][Full Text] [Related]
6. Pathogenic Mutations Associated with Legius Syndrome Modify the Spred1 Surface and Are Involved in Direct Binding to the Ras Inactivator Neurofibromin.
Führer S; Tollinger M; Dunzendorfer-Matt T
J Mol Biol; 2019 Sep; 431(19):3889-3899. PubMed ID: 31401120
[TBL] [Abstract][Full Text] [Related]
7. A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1.
Stowe IB; Mercado EL; Stowe TR; Bell EL; Oses-Prieto JA; Hernández H; Burlingame AL; McCormick F
Genes Dev; 2012 Jul; 26(13):1421-6. PubMed ID: 22751498
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous Findings in Neurofibromatosis Type 1.
Ozarslan B; Russo T; Argenziano G; Santoro C; Piccolo V
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33530415
[TBL] [Abstract][Full Text] [Related]
9. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome.
Messiaen L; Yao S; Brems H; Callens T; Sathienkijkanchai A; Denayer E; Spencer E; Arn P; Babovic-Vuksanovic D; Bay C; Bobele G; Cohen BH; Escobar L; Eunpu D; Grebe T; Greenstein R; Hachen R; Irons M; Kronn D; Lemire E; Leppig K; Lim C; McDonald M; Narayanan V; Pearn A; Pedersen R; Powell B; Shapiro LR; Skidmore D; Tegay D; Thiese H; Zackai EH; Vijzelaar R; Taniguchi K; Ayada T; Okamoto F; Yoshimura A; Parret A; Korf B; Legius E
JAMA; 2009 Nov; 302(19):2111-8. PubMed ID: 19920235
[TBL] [Abstract][Full Text] [Related]
10. Copy number variants and rasopathies: germline KRAS duplication in a patient with syndrome including pigmentation abnormalities.
Gilbert-Dussardier B; Briand-Suleau A; Laurendeau I; Bilan F; Cavé H; Verloes A; Vidaud M; Vidaud D; Pasmant E
Orphanet J Rare Dis; 2016 Jul; 11(1):101. PubMed ID: 27450488
[TBL] [Abstract][Full Text] [Related]
11. Structural Insights into the SPRED1-Neurofibromin-KRAS Complex and Disruption of SPRED1-Neurofibromin Interaction by Oncogenic EGFR.
Yan W; Markegard E; Dharmaiah S; Urisman A; Drew M; Esposito D; Scheffzek K; Nissley DV; McCormick F; Simanshu DK
Cell Rep; 2020 Jul; 32(3):107909. PubMed ID: 32697994
[TBL] [Abstract][Full Text] [Related]
12. The SPRED1 Variants Repository for Legius Syndrome.
Sumner K; Crockett DK; Muram T; Mallempati K; Best H; Mao R
G3 (Bethesda); 2011 Nov; 1(6):451-6. PubMed ID: 22384355
[TBL] [Abstract][Full Text] [Related]
13. Café-au-lait Macules and Neurofibromatosis Type 1: A Review of the Literature.
Bernier A; Larbrisseau A; Perreault S
Pediatr Neurol; 2016 Jul; 60():24-29.e1. PubMed ID: 27212418
[TBL] [Abstract][Full Text] [Related]
14. Predicting neurofibromatosis type 1 risk among children with isolated café-au-lait macules.
Ben-Shachar S; Dubov T; Toledano-Alhadef H; Mashiah J; Sprecher E; Constantini S; Leshno M; Messiaen LM
J Am Acad Dermatol; 2017 Jun; 76(6):1077-1083.e3. PubMed ID: 28318682
[TBL] [Abstract][Full Text] [Related]
15. Family with Legius syndrome (neurofibromatosis type 1-like syndrome).
Sakai N; Maeda T; Kawakami H; Uchiyama M; Harada K; Tsuboi R; Mitsuhashi Y
J Dermatol; 2015 Jul; 42(7):703-5. PubMed ID: 25981987
[TBL] [Abstract][Full Text] [Related]
16. MEK inhibition ameliorates social behavior phenotypes in a Spred1 knockout mouse model for RASopathy disorders.
Borrie SC; Plasschaert E; Callaerts-Vegh Z; Yoshimura A; D'Hooge R; Elgersma Y; Kushner SA; Legius E; Brems H
Mol Autism; 2021 Jul; 12(1):53. PubMed ID: 34311771
[TBL] [Abstract][Full Text] [Related]
17. Choroidal abnormalities in café-au-lait syndromes: a new differential diagnostic tool?
Cassiman C; Casteels I; Jacob J; Plasschaert E; Brems H; Dubron K; Keer KV; Legius E
Clin Genet; 2017 Apr; 91(4):529-535. PubMed ID: 27716896
[TBL] [Abstract][Full Text] [Related]
18. Legius Syndrome and Inflammatory Bowel Disease: A Pediatric Case Report.
Paixao F; Ribeiro L; Costa A; Torre M; Ventura A
Cureus; 2023 Oct; 15(10):e46394. PubMed ID: 37927732
[TBL] [Abstract][Full Text] [Related]
19. Impaired instrumental learning in Spred1
Borrie SC; Horner AE; Yoshimura A; Legius E; Kopanitsa MV; Brems H
Genes Brain Behav; 2021 Jun; 20(5):e12727. PubMed ID: 33624414
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
